Literature DB >> 32016960

Long non-coding RNA UCA1 promotes the progression of paclitaxel resistance in ovarian cancer by regulating the miR-654-5p/SIK2 axis.

Z-Y Li1, X-L Wang, Y Dang, X-Z Zhu, Y-H Zhang, B-X Cai, L Zheng.   

Abstract

OBJECTIVE: Ovarian cancer (OC) is a common tumor in women, and the development of chemoresistance is the major obstacle to its treatment. Long non-coding RNAs (LncRNAs) have been linked to chemoresistance in many cancers. However, the function of lncRNA urothelial carcinoma associated1 (UCA1) in paclitaxel (PTX) resistance of OC is not well elucidated. PATIENTS AND METHODS: Quantitative real-time polymerase chain reaction (qRT-PCR) was used to detect the expression of UCA1, microRNA-654-5p (miR-654-5p) and salt inducible kinase 2 (SIK2). Cell PTX resistance and proliferation were evaluated by 3-(4, 5-dimethyl-2 thiazolyl)-2, 5-diphenyl-2-H-tetrazolium bromide (MTT) assay. The abilities of apoptosis, migration and invasion were measured by Flow cytometry and Transwell assays, respectively. Dual-luciferase reporter assay was used to verify the interaction among UCA1, miR-654-5p and SIK2. Besides, Western blot analysis was performed to assess the protein level of SIK2.
RESULTS: UCA1 was markedly upregulated in OC tissues and PTX-resistant OC cells. Silencing of UCA1 restrained the PTX resistance, reduced the proliferation, migration, invasion and enhanced the apoptosis of PTX-resistant OC cells. MiR-654-5p could be sponged by UCA1, and the inhibitory effect of its overexpression on the progression of PTX-resistant OC cells could be reversed by overexpressed-UCA1. Moreover, SIK2 was a target of miR-654-5p. Silencing of SIK2 could hinder the PTX resistance and suppress the progression of PTX-resistant OC cells, while miR-654-5p inhibitor could invert this inhibitory effect. Also, the expression of SIK2 was regulated by miR-654-5p and UCA1 expression.
CONCLUSIONS: LncRNA UCA1 plays an active role in PTX resistance of OC and is crucial to maintain the development of PTX resistance in OC, which provides a new therapeutic target for the study of OC chemoresistance.

Entities:  

Year:  2020        PMID: 32016960     DOI: 10.26355/eurrev_202001_20035

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  9 in total

Review 1.  The Challenges and Opportunities of LncRNAs in Ovarian Cancer Research and Clinical Use.

Authors:  Martín Salamini-Montemurri; Mónica Lamas-Maceiras; Aida Barreiro-Alonso; Ángel Vizoso-Vázquez; Esther Rodríguez-Belmonte; María Quindós-Varela; María Esperanza Cerdán
Journal:  Cancers (Basel)       Date:  2020-04-21       Impact factor: 6.639

2.  LncRNA UCA1 Enhances Cisplatin Resistance by Regulating CYP1B1-mediated Apoptosis via miR-513a-3p in Human Gastric Cancer.

Authors:  Haidong Cheng; Gaowa Sharen; Zhaoyang Wang; Jing Zhou
Journal:  Cancer Manag Res       Date:  2021-01-14       Impact factor: 3.989

3.  Identification of Novel lncRNAs in Ovarian Cancer and Their Impact on Overall Survival.

Authors:  Nicholas Cardillo; Douglas Russo; Andreea Newtson; Henry Reyes; Yasmin Lyons; Eric Devor; David Bender; Michael J Goodheart; Jesus Gonzalez-Bosquet
Journal:  Int J Mol Sci       Date:  2021-01-22       Impact factor: 5.923

Review 4.  LncRNAs in Ovarian Cancer Progression, Metastasis, and Main Pathways: ceRNA and Alternative Mechanisms.

Authors:  Eleonora A Braga; Marina V Fridman; Alexey A Moscovtsev; Elena A Filippova; Alexey A Dmitriev; Nikolay E Kushlinskii
Journal:  Int J Mol Sci       Date:  2020-11-23       Impact factor: 5.923

5.  LINC02532 Contributes to Radiosensitivity in Clear Cell Renal Cell Carcinoma through the miR-654-5p/YY1 Axis.

Authors:  Xiaoguang Zhou; Bowen Zeng; Yansheng Li; Haozhou Wang; Xiaodong Zhang
Journal:  Molecules       Date:  2021-11-22       Impact factor: 4.411

6.  Genetic variations in UCA1, a lncRNA functioning as a miRNA sponge, determine endometriosis development and the potential associated infertility via regulating lipogenesis.

Authors:  Cherry Yin-Yi Chang; Li Yang; Joe Tse; Lun-Chien Lo; Chung-Chen Tseng; Li Sun; Ming-Tsung Lai; Ping-Ho Chen; Tritium Hwang; Chih-Mei Chen; Fuu-Jen Tsai; Jim Jinn-Chyuan Sheu
Journal:  PLoS One       Date:  2022-07-28       Impact factor: 3.752

Review 7.  Long noncoding RNAs as therapeutic targets to overcome chemoresistance in ovarian cancer.

Authors:  Linjiao Chen; Jie Wang; Qian Liu
Journal:  Front Cell Dev Biol       Date:  2022-08-29

8.  Interference with circRNA DOCK1 inhibits hepatocellular carcinoma cell proliferation, invasion and migration by regulating the miR-654-5p/SMAD2 axis.

Authors:  Yujuan Lu; Jingzhi Zhang; Yanhui Wu
Journal:  Mol Med Rep       Date:  2021-06-29       Impact factor: 2.952

Review 9.  RSF1 in cancer: interactions and functions.

Authors:  Guiyang Cai; Qing Yang; Wei Sun
Journal:  Cancer Cell Int       Date:  2021-06-19       Impact factor: 5.722

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.